🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
EQ
$EQ
🔒 US EquitiesEquillium Inc
AVG HISTORICAL GAP
-1.46%
MAX GAP RECORD
-34.21%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $EQ
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$EQ
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 11, 2026 Earnings Release 2026-11-11 (UNDETERMINED) | 🔮 UPCOMING 🔒 |
| Aug 12, 2026 Earnings Release 2026-08-12 (BEFORE OPEN) |
+0.90%
|
| May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE) |
-3.03%
|
| Mar 25, 2026 Earnings Release 2026-03-25 (AFTER CLOSE) |
-3.40%
|
| Nov 13, 2025 Earnings Release 2025-11-13 (AFTER CLOSE) |
+0.00%
|
| Aug 14, 2025 Earnings Release 2025-08-14 (AFTER CLOSE) |
+2.04%
|
| May 14, 2025 Earnings Release 2025-05-14 (AFTER CLOSE) |
+13.51%
|
| Mar 27, 2025 Earnings Release 2025-03-27 (BEFORE OPEN) |
-34.21%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
6.8%
Bullish Gaps (5)
Bearish Gaps (7)
Neutral / Flat (1)
📖 Intelligence Summary
Equillium, Inc. is a clinical-stage biotechnology company that engages in the development of novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗